🗞️ News #AI data centres could worsen US air pollution "AI firms are exploiting loopholes and lax air pollution enforcement in a race to build new on-site fossil-fuel power plants for data centres across the USA" Written by @bryantfurlow.bsky.social www.thelancet.com/journals/lan...

AI data centres could worsen US air pollution

Artificial intelligence (AI) firms are exploiting loopholes and lax air pollution enforcement in a race to build new on-site fossil-fuel power plants for data centres across the USA. Concerns over air...

thelancet.com

🎙️ New Podcast: The changing treatment landscape in #LungCancer Solange Peters, Lizza Hendriks, and Martin Reck join Jonathan Blott to discuss our new joint Series with The Lancet on therapeutics in lung cancer, launched at #ERS2026. www.thelancet.com/audio-do/sol...

📰 News: Unravelling of #tuberculosis control in Ukraine www.thelancet.com/journals/lan... Written by Talha Burki

❗ #ERSALERTS Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 2–5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study Presented today by Prof Marcus Mall at #ERS2026 www.thelancet.com/journals/lan...

📰 New Series from The Lancet and The Lancet Respiratory Medicine, launched 7th September at #ERS2026 Therapeutics in Lung Cancer www.thelancet.com/series-do/lu... The Series includes three review papers on early stage #NSCLC, advanced NSCLC, and #SCLC 🔓All content is free to access for all

🫁 Lung cancer remains the leading cause of cancer-related death worldwide. A new Lancet–@lancetrespirmed.bsky.social Series, presented at #ERSCongress, evaluates the evolving therapeutic landscape across the major subtypes of lung cancer: spkl.io/633247uqza @europeanrespsoc.bsky.social

🗓️ The Lancet Respiratory Medicine Team are looking forward to #ERS2026 in Barcelona from 5-9th September Please join us on Monday 7th September at 3:30 pm for the launch of our new joint Series with The Lancet on Therapeutics in #LungCancer @europeanrespsoc.bsky.social

🫁 Explore our September 2026 issue, out now in print and online! 🔗 www.thelancet.com/issue/S2213-... 🔹 This issue covers postoperative pulmonary complications, #NSCLC, pulmonary fibrosis of childhood #ILD and much more

📮 New Article available #OpenAccess 📊 A patient-level meta-analysis of RCTs and cohort studies (7161 people) found ACQ-5 symptom scores barely tracked with inflammatory biomarkers. Blood eosinophils and FeNO, by contrast, reliably flagged both risk and treatment response. 🔗 tinyurl.com/3fpzbkp2

Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies

In a large, individual patient-level meta-analysis of randomised controlled trials and translational prospective observational cohort studies, we observed little alignment of symptom burden with other...

thelancet.com

💡New Spotlight - Breathing Space: “A love letter to breath” Read how the Breathing Space Garden created space for previously unspoken experiences of lung disease to be voiced, heard, and understood Written by @katebinnie.bsky.social www.thelancet.com/journals/lan... @asthmaandlung.org.uk

Breathing Space: “A love letter to breath”

It has been nearly 10 years since Havi Carel's Spotlight in The Lancet Respiratory Medicine on breathlessness and the rift between objective measurement and subjective experience. Havi's phenomenologi...

thelancet.com

📨 New Editorial 🔹Our latest editorial reviews evidence that wildfire-specific PM2·5 raises respiratory hospitalisation risk more than ordinary particulate pollution, hitting children, older adults, and low-income communities hardest. tinyurl.com/2sy2fmmr #Wildfires #ClimateChange

❇️ New Article available #OpenAccess Why does #asthma cost the US economy roughly 100 times more than it costs low-income countries — even though LMICs carry the larger share of the disease burden? Read the full paper: www.thelancet.com/journals/lan...

📊 The August issue of The Lancet Respiratory Medicine is out — from equitable #ILD care to new trial data in children's oxygen therapy, severe #asthma biologics, and reproductive health in #cysticfibrosis. Check out the full issue here: www.thelancet.com/issue/S2213-...

🔔 Discover The Lancet Surgery & Anaesthesiology, a new journal with a sharp clinical focus, dedicated to advancing science across the full extent of #surgery, #anaesthesiology, and #perioperative specialties, across the age spectrum, and across the globe: spkl.io/633237JQbc

📊 New Article available #OpenAccess 📈 FEF25–75% trajectories from age 7 to 53 years, associations with childhood and parental preconception factors, and midlife COPD risk: a prospective cohort study Could your risk of #COPD be shaped before you were even born? www.thelancet.com/journals/lan...

Does transformative CF treatment mean transformative reproductive outcomes — and why does the answer differ for men and women? Read the full paper: www.thelancet.com/journals/lan... #CysticFibrosis #CFTRModulators #ReproductiveHealth #LancetRespiratoryMedicine #Pulmonology #WomensHealth #CFCare

From @lancetrespirmed.bsky.social 🫁 #Sugammadex decreased the incidence of postoperative pulmonary complications or mortality compared with #neostigmine in older adults who had major abdominal or #ThoracicSurgery under #GeneralAnesthesia. @katy-skier.bsky.social @prof-nancy-devlin.bsky.social

Postoperative Pulmonary Complications: Sugammadex Outperforms Neostigmine

Sugammadex lowers the risk for postoperative pulmonary complications vs neostigmine after major abdominal or thoracic surgery in older adults.

pulmonologyadvisor.com

📮 July issue out now! Check out the full issue here: www.thelancet.com/issue/S2213-... 📜 Editorial - Dying with Dignity—time to cut the red tape www.thelancet.com/journals/lan... 📰 News Barriers limit oxygen therapy in Nigeria, Kenya, and Uganda by Paul Adepoju www.thelancet.com/journals/lan...

We are the world-leading journal, ranking #1 in:   Journal Impact Factor (34·7) in respiratory system and #CriticalCareMedicine  Scopus CiteScore (48·1) in pulmonary and #RespiratoryMedicine  Explore our high impact and global reach: hubs.li/Q04k_nNQ0    #Pulmonology #pulmcc

Peer review is stronger when reviewers reflect the breadth of global health expertise. If you author or review for a Lancet journal, update your Editorial Manager profile with your health equity & discrimination expertise. tinyurl.com/yrxfvsbm

🗞️ News - Trump Administration sparks furore and resignations over fruit-flavoured #vape authorisations 🔹 White House overrules objections from FDA commissioner, ordering the agency to authorise two fruit-flavoured #eCigarette products @bryantfurlow.bsky.social 🖇️ www.thelancet.com/journals/lan...

Trump Administration sparks furore and resignations over fruit-flavoured vape authorisations

On May 5, the White House overruled objections from US Food and Drug Administration (FDA) commissioner Marty Makary and ordered the agency to authorise sales of two fruit-flavoured e-cigarette product...

thelancet.com

New Article available #OpenAccess 📌 Prevalence and disease trajectories of pulmonary fibrosis of childhood interstitial lung disease: a register-based, multicentre observational study #ILD #chILD #PulmonaryFibrosis 🖇️ www.thelancet.com/journals/lan...

🎙️New Podcast Andrew Bush, Heather Zar, and Fernando de Benedictis on how inhaled corticosteroids have changed the treatment of asthma www.thelancet.com/audio-do/and... Check out the full paper here: www.thelancet.com/journals/lan...

50 years on: how inhaled corticosteroids have changed the treatment of asthma

Inhaled corticosteroids are the foundation of asthma therapy and now, 50 years on from their introduction, is an appropriate time to summarise some of the key studies that have progressed the field. W...

thelancet.com

📊 New Article available #OpenAccess 📌Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial 🔗 www.thelancet.com/journals/lan...

Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial

Sugammadex reduced the incidence of postoperative pulmonary complications or death compared with neostigmine. The risk reduction was small with atelectasis of uncertain clinical significance being the...

thelancet.com

Today is #CleanAirDay Read our latest Editorial - Clean Air Day: breathe locally, plan globally www.thelancet.com/journals/lan...

From @lancetrespirmed.bsky.social 🫁 The link between 60-day mortality and personalized, best-practice mechanical ventilation in patients with #AcuteRespiratoryDistressSyndrome may be stronger in those with hypoinflammatory vs hyperinflammatory ARDS.

In ARDS, Mortality Risk With Mechanical Ventilation Varies by Phenotype

The link between 60-day mortality and MV in patients with ARDS may be stronger in those with hypoinflammatory vs hyperinflammatory ARDS.

pulmonologyadvisor.com

💡 New Spotlight: Africa's inhaler dilemma Esther Nakkazi reports on the issues of cost, climate, and care www.thelancet.com/journals/lan...

Africa's inhaler dilemma: balancing cost, climate, and care

When baby Sidrah Isaacs was born, she appeared well. At around 6 weeks of age, her mother, Sasha Leigh, began to notice concerning symptoms, including a silent cough, a weak cry, and breathing difficu...

thelancet.com

It's official! The SNaPP trial @anzcactn.bsky.social findings are out, published today @lancetrespirmed.bsky.social, a four year trial with principal investigator @katy-skier.bsky.social.

Global study highlights hidden pandemic of lung complications - ANZCA

A “hidden pandemic” of lung complications after surgery has been highlighted by an international study led by Australian anaesthetists that has found how a newer muscle relaxant reversal drug can help...

anzca.edu.au

🌅 Check out the #SUNRISE phase 3 trial of tezepelumab in reducing OCS use in severe, OCS-dependent #asthma 🟥Efficacy and safety of tezepelumab vs placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent #asthma (SUNRISE) tinyurl.com/6h8xtr8w

Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-b...

In this study, tezepelumab treatment led to greater reductions from baseline in daily oral corticosteroid dose than placebo at week 28 despite early study termination. No safety concerns were identifi...

thelancet.com

🏥 June issue of The Lancet Respiratory Medicine available online and in print now! Check out the full issue here: www.thelancet.com/issue/S2213-... 📜 Editorial Clean Air Day: breathe locally, plan globally www.thelancet.com/journals/lan...